Pieris Pharma

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Investors need to pay close attention to for Pieris Pharmaceuticals (PIRS) stock based on the movements in the options market lately.

Do Options Traders Know Something About Pieris Pharmaceuticals (PIRS) Stock We Don't?

BOSTON, MA / ACCESSWIRE / November 11, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor conferences: Jefferies London Healthcare Conference Thursday, November 18, 2021 at 8:00 AM GMT. A webcast of the Company's fireside chat will be available at this link.

Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences

BOSTON, MA and PARIS, FRANCE / ACCESSWIRE / November 8, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, and Servier, a global pharmaceutical group, today announced that the first patient has been dosed in the phase 1/2 study of PRS-344/S095012, a next generation 4-1BB/PD-L1 Anticalin-based bispecific for the treatment of solid tumors, triggering an undisclosed milestone payment to Pieris. The global, open-label phase 1/2 dose escalation study will evaluate the safety, tolerability, potential optimal dosage, and potential anti-tumor activity of PRS-344/S095012 in patients with advanced solid tumors whose cancer progressed on standard-of-care treatment.

Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 0.00% and -49.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Misses Revenue Estimates

Company To Host an Investor Conference Call on Tuesday, November 2, 2021 at 8:00 AM EDT Dosing completed in part 1a of phase 2a study of PRS-060/AZD1402 Dosing to begin this quarter in phase 2 study of cinrebafusp alfa Received regulatory approval from multiple countries for phase 1/2 study of PRS-344/ S095012 Presented preclinical data for PRS-220 at ERS; on track for 2022 clinical initiation Initiated second costim bispecific program in Seagen collaboration Initiated respiratory and ophthalmology programs with Genentech Promoted Thomas Bures to CFO and Ahmed Mousa to CBO BOSTON, MA / ACCESSWIRE / November 2, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today reported financial results for the third quarter of 2021 ended September 30, 2021 and provided an update on the Company's recent and anticipated future developments. "I am pleased to report that AstraZeneca has completed dosing in part 1a of the phase 2a study of PRS-060/AZD1402.

Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

BOSTON, MA / ACCESSWIRE / October 26, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2021 investor call on Tuesday, November 2, 2021 at 8:00 AM EDT to discuss financial results and provide a corporate update. To access the call, participants may dial 877-407-8920 (Toll Free US & Canada) or 412-902-1010 (International) at least five minutes prior to the start of the call.

Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021

Artificial Intelligence Technology Solutions Inc.

Castor Maritime Inc

Longeveron

Rolls-Royce Holdings PLC

With so much chaos occurring on Wall Street, these lesser-known penny stocks to buy might fly profitably under the radar. The post 7 Penny Stocks to Buy to Sidestep the Noise on Wall Street appeared first on InvestorPlace.

7 Penny Stocks to Buy to Sidestep the Noise on Wall Street

Leap Therapeutics

These two tiny drugmakers might be hidden gems.

2 Penny Stocks That Could Soar Soon

ACADIA Pharma

Fate Therapeutics

Biotech companies develop new medicines, vaccines, or medical devices. They use advanced technologies and medical science to do so.

3 Biotech Stocks to Watch Now

BOSTON, MA / ACCESSWIRE / October 6, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the promotions of Thomas Bures to Chief Financial Officer and Ahmed Mousa to Chief Business Officer. "Since joining Pieris four years ago, Tom has demonstrated excellent business and leadership acumen, having played a critical role across the entire spectrum of the corporate finance function during this time," said Stephen S.

Pieris Pharmaceuticals Announces Appointments of Chief Financial Officer and Chief Business Officer

BIOLASE

Boxlight

Are these penny stocks on your watchlist this week? The post Top Penny Stocks to Watch After the Long Weekend appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Watch After the Long Weekend

Bellus Health Inc

CTI BioPharma

ObsEva

These penny stocks could be in focus as we turn the page on a new month. The post 5 Penny Stocks To Watch For September With Upcoming Events appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Watch For September With Upcoming Events

Axsome Therapeutics

AstraZeneca

Nasdaq

Novavax

Roche Holding AG

Cassava Sciences Inc

Seagen

Sanofi

Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?

Which Biotech Stock Will Shock the Market in 2022?

BOSTON, MA / ACCESSWIRE / August 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced today the presentation of preclinical data for PRS-220, a connective tissue growth factor (CTGF) inhibitor the Company is developing for the treatment of idiopathic pulmonary fibrosis (IPF) via oral inhaled administration, at the European Respiratory Society (ERS) International Congress 2021. The poster is now available for viewing by registered participants, and a copy of the poster is available here.

Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -25.00% and -61.47%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Misses Revenue Estimates

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, AUGUST 4, 2021 AT 8:00 AM EDT Announced inhaled program PRS-220 for the treatment of IPF and was selected to receive a Bavarian government grant of approximately $17 million to evaluate the program for post-COVID pulmonary fibrosis Signed respiratory and ophthalmology agreement with Genentech with a $20 million upfront payment and more than $1.4 billion in potential additional milestone payments Tim Demuth, M.D., Ph.D., appointed Chief Medical Officer and Shane Olwill, Ph.D.

Pieris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Tim Demuth, M.D., Ph.D., joins Pieris as Chief Medical Officer Shane Olwill, Ph.D.

Pieris Pharmaceuticals Strengthens Executive R&D Leadership Team

BOSTON, MA / ACCESSWIRE / July 28, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a second quarter 2021 investor call on Wednesday, August 4, 2021 at 8:00 AM EDT to discuss financial results and provide a corporate update. To access the call, participants may dial 877-407-8920 (Toll Free US & Canada) or 412-902-1010 (International) at least five minutes prior to the start of the call.

Pieris Pharmaceuticals to Host Second Quarter 2021 Investor Call and Provide Corporate Update on August 4, 2021

Gran Tierra Energy

IAMGOLD

Meten Holding Group Ltd.

McEwen Mining

Sesen Bio Inc.

Uranium Energy

VistaGen Therapeutics

Making a penny stocks watchlist for 2021? Check these 8 out The post Are These 8 Penny Stocks to Watch on Your List Right Now?

Are These 8 Penny Stocks to Watch on Your List Right Now?

Pieris Pharmaceuticals is introducing a whole new class of drugs to the marketplace.

This Risky Micro-Cap Could Pay Off Big

Pieris Pharmaceuticals Inc (NASDAQ: PIRS) has announced the development of PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor to treat idiopathic pulmonary fibrosis (IPF).  The Company will also receive a €14.2 million (approximately $17 million) grant from the Bavarian Ministry of Economic Affairs, Regional Development, and Energy to research and develop PRS-220 for post-acute COVID-19 pulmonary fibrosis, also known as pulmonary fibrosis secondary to COVID-19 or "long COVID.

Pieris Stock Moves Higher On €14.2M Grant For PRS-220 In Post-COVID Pulmonary Fibrosis

PRS-220, an oral inhaled Anticalin protein targeting CTGF, a fully proprietary drug candidate for respiratory disease, is being developed as a local treatment for idiopathic pulmonary fibrosis Grant to enable the evaluation of PRS-220 for the treatment of post-COVID-19-related pulmonary fibrosis for clinical-readiness in general and initial clinical development of PRS-220 in the post-COVID-19 setting Clinical development of PRS-220 expected to begin in 2022 BOSTON, MA / ACCESSWIRE / June 25, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the development of PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor (CTGF), also known as CCN2, for the treatment of idiopathic pulmonary fibrosis (IPF). The Company also announced it has been selected to receive a 14.2 million euro (approximately 17 million USD) grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy for the research and development of PRS-220 for post-acute sequelae of SARS-CoV-2 infection (PASC) pulmonary fibrosis (PASC-PF), also known as post-COVID-19 syndrome pulmonary fibrosis or "long COVID".

Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis

Aditxt Inc

Sphere 3D

Vinco Ventures

Globalstar

Luokung Technology Corp

MediciNova

New Gold

Qudian

Transocean

Tellurian

US Well Services

Uxin Ltd - ADR

Xeris Biopharma Holdings

These penny stocks are trending right now, here's why The post Best Penny Stocks to Buy Right Now? 15 To Watch In July appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Right Now? 15 To Watch In July

BOSTON, MA / ACCESSWIRE / June 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to cinrebafusp alfa (PRS-343), a 4-1BB/HER2 bispecific, for the treatment of HER2-high and HER2-low expressing gastric cancers. "The granting of orphan drug designation to cinrebafusp alfa underscores the high unmet medical need that persists in the treatment of gastric cancer and reinforces our conviction in the importance of developing this program while setting a high bar for success to help patients with limited therapeutic options," said Stephen S.

Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer

AnPac Bio-Medical Science Co

Are these biotech penny stocks to watch on your list for July 2021? The post Best Biotech Penny Stocks to Buy Next Month?

Best Biotech Penny Stocks to Buy Next Month? 3 For Your Watchlist

News for Pieris Pharma Stock (PIRS)